Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Posted: July 11, 2024 at 2:44 am

Phase 1 HELIOS study evaluates AXPAXLI™ for non-proliferative diabetic retinopathy (NPDR) Phase 1 HELIOS study evaluates AXPAXLI™ for non-proliferative diabetic retinopathy (NPDR)

Read the original here:
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Related Posts